Style | Citing Format |
---|---|
MLA | Amirifar P, et al.. "Ataxia-Telangiectasia: Epidemiology, Pathogenesis, Clinical Phenotype, Diagnosis, Prognosis and Management." Expert Review of Clinical Immunology, vol. 16, no. 9, 2020, pp. 859-871. |
APA | Amirifar P, Ranjouri MR, Lavin M, Abolhassani H, Yazdani R, Aghamohammadi A (2020). Ataxia-Telangiectasia: Epidemiology, Pathogenesis, Clinical Phenotype, Diagnosis, Prognosis and Management. Expert Review of Clinical Immunology, 16(9), 859-871. |
Chicago | Amirifar P, Ranjouri MR, Lavin M, Abolhassani H, Yazdani R, Aghamohammadi A. "Ataxia-Telangiectasia: Epidemiology, Pathogenesis, Clinical Phenotype, Diagnosis, Prognosis and Management." Expert Review of Clinical Immunology 16, no. 9 (2020): 859-871. |
Harvard | Amirifar P et al. (2020) 'Ataxia-Telangiectasia: Epidemiology, Pathogenesis, Clinical Phenotype, Diagnosis, Prognosis and Management', Expert Review of Clinical Immunology, 16(9), pp. 859-871. |
Vancouver | Amirifar P, Ranjouri MR, Lavin M, Abolhassani H, Yazdani R, Aghamohammadi A. Ataxia-Telangiectasia: Epidemiology, Pathogenesis, Clinical Phenotype, Diagnosis, Prognosis and Management. Expert Review of Clinical Immunology. 2020;16(9):859-871. |
BibTex | @article{ author = {Amirifar P and Ranjouri MR and Lavin M and Abolhassani H and Yazdani R and Aghamohammadi A}, title = {Ataxia-Telangiectasia: Epidemiology, Pathogenesis, Clinical Phenotype, Diagnosis, Prognosis and Management}, journal = {Expert Review of Clinical Immunology}, volume = {16}, number = {9}, pages = {859-871}, year = {2020} } |
RIS | TY - JOUR AU - Amirifar P AU - Ranjouri MR AU - Lavin M AU - Abolhassani H AU - Yazdani R AU - Aghamohammadi A TI - Ataxia-Telangiectasia: Epidemiology, Pathogenesis, Clinical Phenotype, Diagnosis, Prognosis and Management JO - Expert Review of Clinical Immunology VL - 16 IS - 9 SP - 859 EP - 871 PY - 2020 ER - |